(Q35209594)

7 August 2017

title

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics (English)

1 reference

7 August 2017

1 reference

Michael A Tortorici

1

1 reference

7 August 2017

Melvin Toh

2

1 reference

7 August 2017

S V Rahavendran

3

1 reference

7 August 2017

Robert R Labadie

4

1 reference

7 August 2017

Christine W Alvey

5

1 reference

7 August 2017

Thomas Marbury

6

1 reference

7 August 2017

Ernesto Fuentes

7

1 reference

7 August 2017

Matthew Green

8

1 reference

7 August 2017

Grace Ni

9

1 reference

7 August 2017

Brian Hee

10

1 reference

7 August 2017

Yazdi K Pithavala

11

1 reference

7 August 2017

language of work or name

1 reference

2 July 2010

1 reference

Investigational New Drugs

7 August 2017

published in

1 reference

7 August 2017

volume

29

1 reference

7 August 2017

issue

6

1 reference

7 August 2017

page(s)

1370-1380

1 reference

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers

7 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171651

The Simcyp population-based ADME simulator

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171651

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171651

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171651

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171651

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171651

Transection of the oesophagus for bleeding oesophageal varices

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171651

A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171651

Hepatic clearance of drugs. III. Additional experimental evidence supporting the "well-stirred" model, using metabolite (MEGX) generated from lidocaine under varying hepatic blood flow rates and linear conditions in the perfused rat liver in situ pr

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171651

Hepatic clearance of drugs. II. Experimental evidence for acceptance of the “well-stirred” model over the “parallel tube” model using lidocaine in the perfused rat liverin situ preparation

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171651

Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171651

Protein Binding and Kinetics of Drugs in Liver Diseases

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171651

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

28 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9477-4

Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9477-4

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9477-4

Evaluation of the protein binding ratio of drugs by a micro-scale ultracentrifugation method

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9477-4

Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171651

10.1007/S10637-010-9477-4

26 September 2018

Identifiers

DOI

1 reference

7 August 2017

1 reference

7 August 2017

1 reference